Adverts

Open Access Articles- Top Results for LY-503,430

LY-503,430

</th></tr>
LY-503,430
200px
Systematic (IUPAC) name
4'-{(1S)-1-fluoro-2-[(isopropylsulfonyl)amino]-1-methylethyl}-N-methylbiphenyl-4-carboxamide
Clinical data
  • Investigational New Medicine
oral
Identifiers
625820-83-9 7pxY
Synonyms LY-503,430; (R)-4'-[1-fluoro-1-methyl-2-(propane-2-sulfonylamino)-ethyl]-biphenyl-4-carboxylic acid methylamide
Chemical data
Formula C20H25FN2O3S
392.49 g/mol
 14pxY (what is this?)  (verify)

LY-503,430 is an ampakine drug developed by Eli Lilly.[1]

LY-503,430 produces both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP and also increasing levels of the neurotrophic factor BDNF in the brain, particularly in the substantia nigra, hippocampus and striatum.[2][3] It is orally active and the main application it is currently being developed for is treatment of Parkinson's Disease although it has also been proposed to be useful in the treatment of Alzheimer's Disease, depression and schizophrenia.[4][5]

References

  1. ^ O'neill, MJ; Murray, TK; Clay, MP; Lindstrom, T; Yang, CR; Nisenbaum, ES (2005). "LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease". CNS Drug Reviews 11 (1): 77–96. PMID 15867954. doi:10.1111/j.1527-3458.2005.tb00037.x. 
  2. ^ Murray, TK; Whalley, K; Robinson, CS; Ward, MA; Hicks, CA; Lodge, D; Vandergriff, JL; Baumbarger, P et al. (2003). "LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease". The Journal of Pharmacology and Experimental Therapeutics 306 (2): 752–62. PMID 12730350. doi:10.1124/jpet.103.049445. 
  3. ^ Ryder, JW; Falcone, JF; Manro, JR; Svensson, KA; Merchant, KM (2006). "Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors". The Journal of Pharmacology and Experimental Therapeutics 319 (1): 293–8. PMID 16803862. doi:10.1124/jpet.106.105734. 
  4. ^ O'neill, MJ; Bleakman, D; Zimmerman, DM; Nisenbaum, ES (2004). "AMPA receptor potentiators for the treatment of CNS disorders". Current drug targets. CNS and neurological disorders 3 (3): 181–94. PMID 15180479. doi:10.2174/1568007043337508. 
  5. ^ O'neill, MJ; Witkin, JM (2007). "AMPA receptor potentiators: application for depression and Parkinson's disease". Current drug targets 8 (5): 603–20. PMID 17504104. doi:10.2174/138945007780618517. 



Lua error in package.lua at line 80: module 'Module:Buffer' not found.